Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study
Joint Authors
Zhang, Chun-yi
Liu, Kaiyan
Yang, Jie
Ren, Zhuxiao
Rao, Yunbei
Zhong, Junjuan
Wang, Zhu
Liu, Zhipeng
Wei, Wei
Lu, Lijuang
Wen, Jiying
Liu, Guocheng
Wang, Qi
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-08-15
Country of Publication
Egypt
No. of Pages
9
Abstract EN
Background.
Preterm birth complications are one of the leading causes of death among children under 5 years of age.
Despite advances in medical care, many survivors face a lifetime of disability, including mental and physical retardation, and chronic lung disease.
More recently, both allogenic and autogenic cord blood cells have been applied in the treatment of neonatal conditions such as hypoxic-ischemic encephalopathy (HIE) and bronchopulmonary dysplasia (BPD).
Objective.
To assess the safety of autologous, volume- and red blood cell- (RBC-) reduced, noncryopreserved umbilical cord blood (UCB) cell infusion to preterm infants.
Method.
This study was a phase I, open-label, single-arm, single-center trial to evaluate the safety of autologous, volume- and RBC-reduced, noncryopreserved UCB cell (5 × 107cells/kg) infusion for preterm infants <37 weeks gestational age.
UCB cell characteristics, pre- and postinfusion vital signs, and laboratory investigations were recorded.
Clinical data including mortality rates and preterm complications were recorded.
Results.
After processing, (22.67 ± 4.05) ml UCB cells in volume, (2.67 ± 2.00) × 108 cells in number, with (22.67 ± 4.05) × 106 CD34+, (3.72 ± 3.25) × 105 colony forming cells (CFU-GM), and (99.7 ± 0.17%) vitality were infused to 15 preterm infants within 8 hours after birth.
No adverse effects were noticed during treatment.
All fifteen patients who received UCB infusion survived.
The duration of hospitalization ranged from 4 to 65 (30 ± 23.6) days.
Regarding preterm complications, no BPD, necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP) was observed.
There were 1/15 (7%) infant with intraventricular hemorrhage (IVH), 5/15 (33.3%) infants with ventilation-associated pneumonia, and 10/15 (66.67%) with anemia, respectively.
Conclusions.
Collection, preparation, and infusion of fresh autologous UCB cells to preterm infants is feasible and safe.
Adequately powered randomized controlled studies are needed.
American Psychological Association (APA)
Yang, Jie& Ren, Zhuxiao& Zhang, Chun-yi& Rao, Yunbei& Zhong, Junjuan& Wang, Zhu…[et al.]. 2018. Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study. Stem Cells International،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1213457
Modern Language Association (MLA)
Yang, Jie…[et al.]. Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study. Stem Cells International No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1213457
American Medical Association (AMA)
Yang, Jie& Ren, Zhuxiao& Zhang, Chun-yi& Rao, Yunbei& Zhong, Junjuan& Wang, Zhu…[et al.]. Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study. Stem Cells International. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1213457
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1213457